Stock Markets
Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data
On Monday, Silence Therapeutics (NASDAQ:SLN) received a positive outlook from Jefferies, as the firm initiated coverage on the biotechnology company’s stock with a Buy rating and a price target of $40.00. Jefferies highlighted the potential of the company’s lead siRNA candidate, which has shown significant efficacy in lowering Lp(a), a causal risk factor for cardiovascular disease, by more than 90%.
The analyst from Jefferies noted that key opinion leaders (KOLs) believe Silence Therapeutics’ siRNA candidate stands out due to its efficacy and the less frequent injections required compared to similar programs. This favorable profile positions the candidate to potentially tap into a market worth over $20 billion.
Additionally, the company’s second candidate for treating Polycythemia Vera (PV), a hematologic disease that affects approximately 100,000 patients in the United States, has demonstrated promising Phase 1 data. The ongoing progress and updates from both the Lp(a)-lowering program and the PV treatment are expected to act as near-term catalysts for the company throughout 2024.
The endorsement from Jefferies comes at a time when Silence Therapeutics is actively developing its pipeline. The company’s focus on RNA interference (RNAi) technology for the treatment of diseases with unmet medical needs has positioned it as a notable player in the biotech industry.
Investors and stakeholders in the biotechnology sector are keeping an eye on Silence Therapeutics as it advances its clinical programs. The company’s progress and potential market opportunities are anticipated to influence its stock performance in the near future.
In other recent news, Silence Therapeutics has made significant strides in the biotechnology sector with its drug development programs. The company reported positive trial results for zerlasiran and divesiran, prompting H.C. Wainwright and BMO Capital Markets to maintain their Buy and Outperform ratings respectively. The potential of these drugs to generate over $1 billion in annual revenue is seen as a key factor in these ratings.
Silence Therapeutics has also received a $2.0 million milestone payment from Hansoh Pharmaceutical Group Company Limited, marking the second milestone in their partnership to develop short interfering RNAs using Silence’s mRNAi GOLD™ platform. This financial boost signifies growth and progress in the firm’s research endeavors.
In terms of personnel changes, the company announced the retirement of board member Alistair Gray. Despite this change, the firm is expected to continue its development and potential commercialization of its therapies, backed by a robust financial position with over $200 million expected to last into 2026.
InvestingPro Insights
As Silence Therapeutics (NASDAQ:SLN) garners attention with a positive outlook from Jefferies, investors may find additional context through InvestingPro data and tips. With a market capitalization of $893.37 million and a high Price / Book multiple of 6.05 as of the last twelve months leading up to Q2 2024, the company is trading at a valuation that reflects investor optimism about its future prospects. Despite a notable year-over-year revenue decline of 37.44%, the company’s liquid assets surpass its short-term obligations, providing financial flexibility as it continues to develop its siRNA candidate and other clinical programs.
According to InvestingPro Tips, Silence Therapeutics holds more cash than debt, which is a positive sign for financial stability. However, analysts do not expect the company to be profitable this year, reflecting the typical high research and development costs associated with the biotech industry. This is underscored by the company’s negative return on assets of -28.51% in the same period. On the brighter side, the company has experienced a significant return over the last year, with a price total return of 124.59%, showcasing the market’s strong response to its potential.
For investors seeking a deeper dive into Silence Therapeutics’ financials and market performance, there are additional InvestingPro Tips available at https://www.investing.com/pro/SLN. These tips could provide further insights into the company’s valuation and potential investment risks and opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
Allbirds stock touches 52-week low at $7.65 amid market challenges
In a challenging market environment, Allbirds Inc. (NASDAQ:) stock has recorded a new 52-week low, dipping to $7.65. The eco-friendly footwear company has faced significant headwinds over the past year, reflected in a substantial 1-year change with a decline of -55.8%. Investors have shown concern as the brand navigates through a competitive retail landscape and supply chain issues, which have pressured the stock to its current low. The company’s efforts to rebound will be closely watched by market participants looking for signs of a turnaround or further indications of industry-wide pressures.
In other recent news, Allbirds disclosed its Q3 2024 financial results, reporting a net revenue of $43 million. This figure reflects a downturn due to reduced unit sales and transitions to a distributor model in certain regions. Despite these challenges, the company managed to increase its gross margin to 44.4%, attributed to lower freight costs and improved inventory management.
The company also launched two new products, the Tree Glider and Lounger Lift, which have been positively received by consumers. Allbirds revised its full-year revenue guidance to between $187 million and $193 million and anticipates an adjusted EBITDA loss of $75 million to $71 million.
Additionally, Allbirds has signed two new international distributor agreements, expanding its reach in Latin America and Europe from mid-2025. The company’s management, led by CEO Joe Vernachio and CFO Annie Mitchell, remains optimistic about future growth, driven by forthcoming product launches and strategic marketing efforts.
InvestingPro Insights
Allbirds Inc. (BIRD) continues to face significant challenges, as reflected in its recent stock performance and financial metrics. According to InvestingPro data, the company’s revenue growth has declined by 22.67% over the last twelve months as of Q3 2024, with a quarterly revenue decline of 24.89% in Q3 2024. This aligns with the InvestingPro Tip that analysts anticipate sales decline in the current year.
The company’s financial health is also concerning, with an operating income margin of -48.08% for the same period. An InvestingPro Tip highlights that Allbirds is quickly burning through cash, which is particularly worrisome given the current market conditions.
Despite these challenges, InvestingPro Tips indicate that Allbirds holds more cash than debt on its balance sheet and its liquid assets exceed short-term obligations. This could provide some financial flexibility as the company navigates its turnaround efforts.
For investors seeking a more comprehensive analysis, InvestingPro offers 17 additional tips for Allbirds, providing a deeper understanding of the company’s financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
Quipt Home Medical stock hits 52-week low at $2.55
Quipt Home Medical (TASE:) Corp. (QIPT) stock has reached a new 52-week low, trading at $2.55. This latest price point marks a significant downturn for the company, which has experienced a 46.87% decline over the past year. Investors are closely monitoring the home medical equipment provider as it navigates through a challenging period marked by this notable decrease in stock value. The 52-week low serves as a critical indicator for the market, reflecting investor sentiment and potential shifts in the company’s financial health and operational performance.
In other recent news, Quipt Home Medical Corp has been making notable strides despite facing several challenges. The company’s third fiscal quarter report revealed a steady increase in revenue, reaching $64 million, a 6.1% rise from the previous year. The customer base also expanded by 9%, serving 153,223 unique patients, and adjusted EBITDA grew by 2.7% to $14.2 million.
Benchmark revised its stock price target for Quipt Home Medical, reducing it to $7 from the previous $9, but maintained a Buy rating for the stock. This adjustment was influenced by several factors including the expiration of Medicare’s 75/25 rate relief, a diminished Managed Care contract, and the repercussions of the Change Healthcare (NASDAQ:) cyberattack. However, the firm predicts that Quipt could achieve an 8%-10% organic growth rate by the second quarter of fiscal year 2025.
In the face of these challenges, Quipt Home Medical has reported a 9% increase in resupply revenue for sleep therapy and supplies, which accounts for half of the company’s revenues. The company’s management has also indicated an active mergers and acquisitions pipeline, which could provide further growth opportunities. These are the recent developments that investors should keep an eye on.
InvestingPro Insights
Despite Quipt Home Medical Corp. (QIPT) hitting a new 52-week low, InvestingPro data reveals some interesting insights that may provide context for investors. The company’s revenue growth remains strong, with a 29.31% increase over the last twelve months as of Q3 2024, reaching $244.23 million. This growth suggests that QIPT continues to expand its market presence in the home medical equipment sector.
However, profitability remains a concern. InvestingPro Tips highlight that QIPT has not been profitable over the last twelve months, with a negative P/E ratio of -24.61. On a more positive note, analysts predict that the company will become profitable this year, which could potentially reverse the stock’s downward trend.
The current market valuation implies a strong free cash flow yield, according to another InvestingPro Tip. This could indicate that the stock may be undervalued at its current price, especially considering that it’s trading near its 52-week low. Investors looking for a deeper analysis can find 7 additional InvestingPro Tips for QIPT, offering a more comprehensive view of the company’s financial situation and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
Muslims who voted for Trump upset by his pro-Israel cabinet picks
By Andrea Shalal
WASHINGTON (Reuters) – U.S. Muslim leaders who supported Republican Donald Trump to protest against the Biden administration’s support for Israel’s war on Gaza and attacks on Lebanon have been deeply disappointed by his Cabinet picks, they tell Reuters.
“Trump won because of us and we’re not happy with his Secretary of State pick and others,” said Rabiul Chowdhury, a Philadelphia investor who chaired the Abandon Harris campaign in Pennsylvania and co-founded Muslims for Trump. Muslim support for Trump helped him win Michigan and may have factored into other swing state wins, strategists believe.
Trump picked Republican senator Marco Rubio, a staunch supporter of Israel for Secretary of State. Rubio said earlier this year he would not call for a ceasefire in Gaza, and that he believed Israel should destroy “every element” of Hamas. “These people are vicious animals,” he added.
Trump also nominated Mike Huckabee, a former Arkansas governor and staunch pro-Israel conservative who backs Israeli occupation of the West Bank and has called a two state solution in Palestine “unworkable”, as the next ambassador to Israel.
He has picked Republican Representative Elise Stefanik, who called the UN a “cesspool of antisemitism” for its condemnation of deaths in Gaza, to serve as U.S. ambassador to the United Nations.
Rexhinaldo Nazarko, executive director of the American Muslim Engagement and Empowerment Network (AMEEN), said Muslim voters had hoped Trump would choose Cabinet officials who work toward peace, and there was no sign of that.
“We are very disappointed,” he said. “It seems like this administration has been packed entirely with neoconservatives and extremely pro-Israel, pro-war people, which is a failure on the on the side of President Trump, to the pro-peace and anti-war movement.”
Nazarko said the community would continue pressing to make its voices heard after rallying votes to help Trump win. “At least we’re on the map.”
Hassan Abdel Salam, a former professor at the University of Minnesota, Twin Cities and co-founder of the Abandon Harris campaign, which endorsed Green Party candidate Jill Stein, said Trump’s staffing plans were not surprising, but had proven even more extreme that he had feared.
“It’s like he’s going on Zionist overdrive,” he said. “We were always extremely skeptical…Obviously we’re still waiting to see where the administration will go, but it does look like our community has been played.”
The Trump campaign did not immediately respond to an email seeking comment.
Several Muslim and Arab supporters of Trump said they hoped Richard Grenell, Trump’s former acting director of national intelligence, would play a key role after he led months of outreach to Muslim and Arab American communities, and was even introduced as a potential next secretary of state at events.
Another key Trump ally, Massad Boulos, the Lebanese father-in-law of Trump’s daughter Tiffany, met repeatedly with Arab American and Muslim leaders.
Both promised Arab American and Muslim voters that Trump was a candidate for peace who would act swiftly to end the wars in the Middle East and beyond. Neither was immediately reachable.
Trump made several visits to cities with large Arab American and Muslim populations, include a stop in Dearborn, a majority Arab city, where he said he loved Muslims, and Pittsburgh, where he called Muslims for Trump “a beautiful movement. They want peace. They want stability.”
Rola Makki, the Lebanese American, Muslim vice chair for outreach of the Michigan Republican Party, shrugged off the criticism.
“I don’t think everyone’s going to be happy with every appointment Trump makes, but the outcome is what matters,” she said. “I do know that Trump wants peace, and what people need to realize is that there’s 50,000 dead Palestinians and 3,000 dead Lebanese, and that’s happened during the current administration.”
- Forex2 years ago
Forex Today: the dollar is gaining strength amid gloomy sentiment at the start of the Fed’s week
- Forex2 years ago
How is the Australian dollar doing today?
- Forex2 years ago
Dollar to pound sterling exchange rate today: Pound plummeted to its lowest since 1985
- Forex2 years ago
Unbiased review of Pocket Option broker
- Cryptocurrency2 years ago
What happened in the crypto market – current events today
- World2 years ago
Why are modern video games an art form?
- Commodities2 years ago
Copper continues to fall in price on expectations of lower demand in China
- Forex2 years ago
The dollar is down again against major world currencies